Building Better Collaboration: Reducing Care Delays in Managing mCRC

Author(s):

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Melody Chang, RPh, MBA, BCOP

Experts discuss proactive steps health care teams, including pharmacists, can take to minimize delays and overcome payer-related barriers when prescribing third-line therapies for metastatic colorectal cancer (mCRC) and how collaboration between health care teams, payers, and manufacturers can be improved to reduce care delays.

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

Now Viewing

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What proactive steps can health care teams, including pharmacists, take to minimize delays and overcome payer-related barriers when prescribing third-line therapies?
How can collaboration between health care teams, payers, and manufacturers be improved to reduce delays in care for patients with mCRC?